Intellia Therapeutics Inc (NASDAQ:NTLA) has been assigned an average recommendation of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $26.36.
A number of equities research analysts have recently weighed in on the company. Evercore ISI assumed coverage on Homology Medicines in a report on Thursday, April 11th. They set an “outperform” rating and a $29.00 target price for the company. Robert W. Baird assumed coverage on Intellia Therapeutics in a report on Monday, July 8th. They set an “outperform” rating and a $23.00 target price for the company. Wedbush reissued an “outperform” rating on shares of Idera Pharmaceuticals in a report on Friday, May 3rd. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, Chardan Capital reissued a “buy” rating and set a $57.50 target price on shares of Intellia Therapeutics in a report on Tuesday, May 28th.
Several hedge funds and other institutional investors have recently modified their holdings of NTLA. Commonwealth Equity Services LLC grew its holdings in Intellia Therapeutics by 59.7% during the second quarter. Commonwealth Equity Services LLC now owns 22,589 shares of the company’s stock worth $369,000 after buying an additional 8,440 shares in the last quarter. Elmwood Wealth Management Inc. grew its holdings in Intellia Therapeutics by 122.1% during the first quarter. Elmwood Wealth Management Inc. now owns 136,849 shares of the company’s stock worth $2,337,000 after buying an additional 75,227 shares in the last quarter. ARK Investment Management LLC grew its holdings in Intellia Therapeutics by 17.3% during the first quarter. ARK Investment Management LLC now owns 7,981,198 shares of the company’s stock worth $136,319,000 after buying an additional 1,179,246 shares in the last quarter. Resources Investment Advisors Inc. bought a new stake in Intellia Therapeutics during the first quarter worth $92,000. Finally, NumerixS Investment Technologies Inc bought a new stake in Intellia Therapeutics during the first quarter worth $110,000. Institutional investors own 74.34% of the company’s stock.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.04. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. The company had revenue of $10.43 million during the quarter, compared to the consensus estimate of $9.43 million. During the same quarter last year, the firm earned ($0.51) earnings per share. The company’s revenue was up 39.7% on a year-over-year basis. Research analysts expect that Intellia Therapeutics will post -2.4 EPS for the current year.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.